Skip to main content

Prothena Corporation PLC (PRTA)

NASDAQ: PRTA · IEX Real-Time Price · USD
61.15 1.19 (1.98%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap2.79B
Revenue (ttm)60.75M
Net Income (ttm)-70.39M
Shares Out45.05M
EPS (ttm)-1.71
PE Ration/a
Forward PE64.10
Dividendn/a
Ex-Dividend Daten/a
Volume279,884
Open59.95
Previous Close59.96
Day's Range59.37 - 61.85
52-Week Range10.72 - 79.75
Beta1.45
AnalystsBuy
Price Target83.38 (+36.4%)
Est. Earnings DateNov 4, 2021

About PRTA

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, ...

IndustryBiotechnology
Founded2012
CEOGene Kinney
Employees66
Stock ExchangeNASDAQ
Ticker SymbolPRTA
Full Company Profile

Financial Performance

In 2020, Prothena's revenue was $853,000, an increase of 4.79% compared to the previous year's $814,000. Losses were -$111.14 million, 43.1% more than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for Prothena stock is "Buy." The 12-month stock price forecast is 83.38, which is an increase of 36.35% from the latest price.

Price Target
$83.38
(36.35% upside)
Analyst Consensus: Buy

News

Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline

Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.

6 days ago - Zacks Investment Research

VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?

VRTX vs. PRTA: Which Stock Is the Better Value Option?

Other symbols:VRTX
1 week ago - Zacks Investment Research

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dys...

2 weeks ago - GlobeNewsWire

Prothena Announces Executive Appointments

Expanded roles support the continued transition to a fully integrated biotechnology company focused on rare peripheral amyloid and neurodegenerative diseases Expanded roles support the continued transit...

2 weeks ago - GlobeNewsWire

VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?

VRTX vs. PRTA: Which Stock Is the Better Value Option?

Other symbols:VRTX
4 weeks ago - Zacks Investment Research

With Prothena Up Over 500% This Year, Is It Too Late to Get in?

Promising drug candidates could lead to a best-in-class Alzheimer's treatment.

1 month ago - The Motley Fool

Here's Why Prothena (PRTA) is a Great Momentum Stock to Buy

Does Prothena (PRTA) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago - Zacks Investment Research

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dy...

1 month ago - GlobeNewsWire

Prothena to Participate in Upcoming September Healthcare Conferences

DUBLIN, Ireland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregul...

1 month ago - GlobeNewsWire

Prothena CEO breaks down the biotech firm's clinical trial timeline for therapeutics

Gene Kinney, the president and CEO of Prothena, explained on Tuesday's "Mad Money" where the biotechnology company's therapeutics stand across the development timeline.

1 month ago - CNBC Television

Here is Why Prothena (PRTA) is Up More Than 155% in Three Months

Prothena (PRTA) surges substantially in the past three months on solid prospects of its AD candidates following Biogen???s AD drug approval.

2 months ago - Zacks Investment Research

Prothena (PRTA) Q2 Earnings Top Estimates, Pipeline in Focus

Prothena's (PRTA) earnings for the second quarter of 2021 beat estimates. Its pipeline remains in focus as the company expects to receive milestone payments from partners.

2 months ago - Zacks Investment Research

Prothena (PRTA) Q2 Earnings Top Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 1.75% and -0.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Recap: Prothena Corp Q2 Earnings

Shares of Prothena Corp (NASDAQ:PRTA) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 187.88% year over year to $0.58, which beat the est...

2 months ago - Benzinga

Prothena Reports Second Quarter 2021 Financial Results and Business Highlights

DUBLIN, Ireland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dys...

2 months ago - GlobeNewsWire

Prothena (PRTA) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Prothena to Report Second Quarter 2021 Financial Results on August 5th

DUBLIN, Ireland, July 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dys...

2 months ago - GlobeNewsWire

Why Is Novo Nordisk Buying a Rare-Disease Candidate?

The company is mainly known for its diabetes drugs but has some background in rare-disease drugs.

Other symbols:NVO
2 months ago - The Motley Fool

Got $2,500? Check Out These 3 Alzheimer's Therapy Stocks

Treating Alzheimer's is extremely difficult, but these innovative companies are taking a stab at it.

Other symbols:ANVSLLY
3 months ago - The Motley Fool

VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?

VRTX vs. PRTA: Which Stock Is the Better Value Option?

Other symbols:VRTX
3 months ago - Zacks Investment Research

Where Prothena Corp Stands With Analysts

Prothena Corp (NASDAQ:PRTA) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 2 0 2 0 Somewhat Bullish 1 0 1 0 Indifferent 0 ...

3 months ago - Benzinga

Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk

Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.

Other symbols:NVO
3 months ago - Zacks Investment Research

Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B

Novo Nordisk A/S (NYSE: NVO) will acquire Prothena Corporation plc's  (NASDAQ: PRTA) and clinical stage antibody PRX004 and broader ATTR amyloidosis program. PRX004 is a Phase 2 ready immunotherapy desi...

Other symbols:NVO
3 months ago - Benzinga

Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion

Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp's experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday.

Other symbols:NVO
3 months ago - Reuters

Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena's ATTR Amyloidosis Programme

DUBLIN, Ireland and BAGSVÆRD, Denmark, July 12, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) and Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have e...

3 months ago - GlobeNewsWire